Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Simulations Plus Stock Up 0.9 %
Simulations Plus stock traded up $0.60 during trading hours on Friday, hitting $66.88. The stock had a trading volume of 90,355 shares, compared to its average volume of 141,332. The company has a 50-day moving average of $53.16 and a two-hundred day moving average of $47.31. The company has a market cap of $1.35 billion, a PE ratio of 117.34 and a beta of 0.42. Simulations Plus has a fifty-two week low of $35.18 and a fifty-two week high of $66.92.
Simulations Plus (NASDAQ:SLP - Get Rating) last posted its quarterly earnings results on Wednesday, July 6th. The technology company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03. The firm had revenue of $14.96 million during the quarter, compared to analysts' expectations of $14.33 million. Simulations Plus had a return on equity of 6.91% and a net margin of 22.74%. The company's revenue for the quarter was up 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.18 EPS. As a group, analysts forecast that Simulations Plus will post 0.64 EPS for the current fiscal year.
Simulations Plus Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Monday, July 25th were issued a $0.06 dividend. The ex-dividend date was Friday, July 22nd. This represents a $0.24 annualized dividend and a yield of 0.36%. Simulations Plus's dividend payout ratio (DPR) is 42.11%.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Craig Hallum increased their target price on Simulations Plus from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, July 7th. TheStreet upgraded Simulations Plus from a "c+" rating to a "b-" rating in a research note on Friday, July 22nd.
Insider Transactions at Simulations Plus
In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Friday, May 27th. The stock was sold at an average price of $47.99, for a total value of $959,800.00. Following the completion of the transaction, the director now directly owns 4,157,634 shares of the company's stock, valued at approximately $199,524,855.66. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction on Friday, May 27th. The stock was sold at an average price of $47.99, for a total transaction of $959,800.00. Following the completion of the sale, the director now directly owns 4,157,634 shares of the company's stock, valued at approximately $199,524,855.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Walter S. Woltosz sold 17,461 shares of the firm's stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $48.00, for a total value of $838,128.00. Following the sale, the director now directly owns 4,140,173 shares of the company's stock, valued at $198,728,304. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,461 shares of company stock valued at $3,021,728. Corporate insiders own 23.08% of the company's stock.
